This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PAND Pandion Therapeutics (PAND) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pandion Therapeutics Stock (NASDAQ:PAND) 30 days 90 days 365 days Advanced Chart Get Pandion Therapeutics alerts:Sign Up Key Stats Today's Range$60.05▼$60.0550-Day Range$59.90▼$60.2852-Week Range$10.28▼$62.90VolumeN/AAverage Volume355,921 shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, develops various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprising an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a tethered bifunctional molecule that utilizes its IL-2 mutein effector module coupled with a MAdCAM-tether module to deliver the IL-2 mutein effector to the gastrointestinal tract where MAdCAM is expressed. It has a license and collaboration agreement with Astellas Pharma Inc. to discover and develop novel compounds for autoimmune diseases of the pancreas, including type 1 diabetes. The company was formerly known as Immunotolerance, Inc. and changed its name to Pandion Therapeutics, Inc. in June 2017. Pandion Therapeutics, Inc. was incorporated in 2016 and is headquartered in Watertown, Massachusetts. Read More Receive PAND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pandion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PAND Stock News HeadlinesFlagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient TherapeuticsApril 29, 2025 | finance.yahoo.comSionna Therapeutics Announces the Appointment of Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of DirectorsJanuary 8, 2025 | finance.yahoo.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 14 at 2:00 AM | Brownstone Research (Ad)SEC settles insider trading case tied to theft from law firm CovingtonSeptember 18, 2024 | reuters.comLawsuits News | Today's Latest Stories | ReutersSeptember 17, 2024 | reuters.comPandion Therapeutics, Inc.September 10, 2024 | reuters.comSEC widens insider-trading case involving stolen law firm M&A infoSeptember 10, 2024 | reuters.comImmunomodulators Market Size to Worth USD 155.66 Billion by 2033August 27, 2024 | finance.yahoo.comSee More Headlines PAND Stock Analysis - Frequently Asked Questions How were Pandion Therapeutics' earnings last quarter? Pandion Therapeutics, Inc. (NASDAQ:PAND) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.07. The firm earned $2.63 million during the quarter, compared to analyst estimates of $1 million. When did Pandion Therapeutics IPO? Pandion Therapeutics (PAND) raised $94 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 5,500,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. What other stocks do shareholders of Pandion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pandion Therapeutics investors own include Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), eBay (EBAY), Garmin (GRMN) and JD.com (JD). Company Calendar Last Earnings11/16/2020Today7/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PAND CIKN/A Webwww.pandiontx.com Phone617-393-5925FaxN/AEmployees56Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$970 thousand Price / Sales1,827.25 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares29,516,000Free FloatN/AMarket Cap$1.77 billion OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PAND) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pandion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pandion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.